# A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT07154290** · PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 300 (estimated)

## Conditions studied

- Advanced/Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Ubamatamab
- **DRUG:** REGN7075
- **DRUG:** Sarilumab

## Key facts

- **NCT ID:** NCT07154290
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2030-06-24
- **Final completion:** 2030-06-24
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07154290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07154290, "A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07154290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*